4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
Deep dive into TRAVERSE trial follow-up and extension data on testosterone replacement therapy cardiovascular safety in hypogonadal men, including long-term MACE outcomes and emerging safety signals.
Deep-dive into the TRAVERSE trial's pre-specified and post-hoc subgroup analyses for testosterone gel in hypogonadal men with elevated cardiovascular risk, examining responses by age, BMI, baseline testosterone, race, and comorbidity burden.
A detailed plain-English breakdown of the TRAVERSE trial (2023), the largest randomized controlled trial of testosterone replacement therapy, which tested cardiovascular safety in over 5,200 hypogonadal men with elevated CV risk.
How the TRAVERSE trial's cardiovascular safety data for testosterone replacement therapy should reshape prescribing decisions, guideline updates, and patient selection in 2024 and beyond.